文献速递中医内科中药与中成药合理使用

灯盏生脉胶囊治疗射血分数保留型心衰的疗效与机制研究

Investigation of the efficacy of Dengzhan Shengmai capsule against heart failure with preserved ejection fraction.
PubMed 文献 · J Ethnopharmacol · 2024-06-03

本研究通过网络药理学预测及小鼠模型验证,探讨灯盏生脉胶囊(DZSMC)治疗射血分数保留型心衰(HFpEF)的疗效与微血管炎症机制。小鼠经单肾切除并持续输注醛固酮0.3 μg/h共4周造模,灌胃给药4周。结果显示DZSMC可改善心肌肥厚与心功能,降低sST2、IL1RL1、CRP、IL-6及VCAM、E-SELECTIN水平,提示其通过调控微血管炎症改善HFpEF。

要点

  • DZSMC可改善HFpEF小鼠心肌肥厚、心肌纤维增殖及线粒体形态功能。
  • DZSMC降低血清sST2、IL1RL1、CRP、IL-6等全身炎症标志物。
  • DZSMC降低VCAM、E-SELECTIN等微血管炎症指标,机制与调控微血管炎症相关。

核心结论

  • 灯盏生脉胶囊通过调控微血管炎症改善射血分数保留型心衰,提供新的证据。

研究设计与样本

  • 研究先采用网络药理学预测DZSMC抗HFpEF的疗效,再进行小鼠实验验证。
  • SPF级小鼠适应喂养3天后,模型组、DZSMC组和卡托普利组行单肾切除,背部植入微泵以0.3 μg/h速率持续输注醛固酮4周。
  • 小鼠灌胃给予DZSMC或卡托普利4周,评估心脏功能、心脏超声及血生化指标。

主要发现

  • DZSMC可改善过度心肌应激所致的心肌肥厚和心肌细胞损伤,减轻长期心脏损害。
  • DZSMC有助于恢复心肌纤维增殖并改善线粒体形态和功能。
  • 在心室肥厚和左心室功能障碍的小鼠模型中,DZSMC干预后心脏功能障碍和心室肥厚减轻。
  • DZSMC干预降低血清sST2、IL1RL1、CRP和IL-6等慢性全身炎症标志物水平。
  • DZSMC干预后VCAM和E-SELECTIN等微血管炎症指标水平也下降。

临床怎么用

  • 对于HFpEF患者,可考虑在中医辨证指导下使用灯盏生脉胶囊,以改善心功能并减轻炎症。
  • 临床监测可关注sST2、IL1RL1、CRP、IL-6及VCAM、E-SELECTIN等炎症标志物变化。

局限性

  • 研究仅为动物实验和网络药理学预测,尚未在临床人群中验证。
  • 样本量、具体统计值和安全性数据未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Heart failure with preserved ejection fraction (HFpEF) has emerged as a condition with high incidence and mortality rates in recent years. Dengzhan Shengmai capsule (DZSMC) is a Chinese patent medicine based on the classic recipe "Shengmai powder". The relevant Chinese medicine ratio of Erigeron breviscapus (Vaniot) Hand.-Mazz., Panax ginseng C.A.Mey., Schisandra chinensis (Turcz.) Baill., and Ophiopogon japonicus (Thunb.) Ker Gawl. Is 30 : 6: 6 : 11. Traditional Chinese medicine (TCM) is being increasingly explored as a safe and effective treatment modality for HFpEF. Clinical studies have shown that DZSMCs can effectively treat heart failure, however, the mechanism of action of DZSMCs in the treatment of HFpEF are still not clear. AIM OF THE STUDY: To investigate the efficacy and underlying mechanisms of Dengzhan Shengmai capsule (DZSMC), in the treatment of HFpEF by focusing on its ability to treat microvascular inflammation. MATERIALS AND METHODS: First, the efficacy of DZSMCs against HFpEF was predicted by network pharmacology. After 3 days of adaptive feeding in SPF-grade polypropylene cages, the mice in the Model group, DZSMC group, and Captopli group underwent single kidney resection, and micropumps were implanted in their backs for continuous infusion of aldosterone at a rate of 0.3 μg/h for 4 weeks. Moreover, the mice were given DZSMCs or Captopli via oral gavage for four weeks. Overall, cardiac function was evaluated in mice, and cardiac ultrasound and blood biochemical indices were evaluated in HFpEF mice. RESULTS: DZSMCs can ameliorate myocardial hypertrophy and cardiomyocyte damage caused by excessive myocardial stress, ultimately mitigating long-term cardiac impairment; it aids in the restoration of myocardial fibre proliferation and enhances mitochondrial morphology and function. In a murine model of ventricular hypertrophy and left ventricular dysfunction, which are indicative of cardiac insufficiency, the administration of DZSMCs resulted in notable improvements. Echocardiographic and overall assessments of cardiac function revealed a reduction in cardiac dysfunction and ventricular hypertrophy post-DZSMC intervention. Moreover, intervention with DZSMCs led to a reduction in the serum levels of several markers associated with chronic systemic inflammation, such as sST2, IL1RL1, CRP, and IL-6. Simultaneously, the levels of indicators of microvascular inflammation, including VCAM and E-SELECTIN, also decreased following DZSMC intervention. These findings suggest the potential multifaceted impact of DZSMCs in alleviating cardiac abnormalities, mitigating systemic inflammation, and reducing microvascular inflammatory markers, highlighting their promising therapeutic role in managing myocardial health. CONCLUSIONS: These results provide novel evidence that DZSMCs improve HFpEF by regulating microvascular inflammation.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Kang Z, Wu Y, Ding Y, et al. Investigation of the efficacy of Dengzhan Shengmai capsule against heart failure with preserved ejection fraction. J Ethnopharmacol. 2024. PMID: 38838924. doi:10.1016/j.jep.2024.118419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。